Complications of Anticoagulation

Disease-a-Month

Volumn 58, Issue 8, 2012, Pages 440-447

  Bilen, Ozlem ^a   Teruya, Jun ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; ANTIFUNGAL AGENT; ARGATROBAN; BARBITURIC ACID DERIVATIVE; CAPECITABINE; CARBAMAZEPINE; CIMETIDINE; COLESTYRAMINE; DABIGATRAN; ESTROGEN; FLUOROURACIL; GREEN TEA EXTRACT; HEPARIN; LEPIRUDIN; LEVOTHYROXINE; LOW MOLECULAR WEIGHT HEPARIN; MACROLIDE; METRONIDAZOLE; OMEPRAZOLE; PHENYTOIN; QUINOLONE DERIVATIVE; SALVIA MILTIORRHIZA EXTRACT; THROMBOCYTE FACTOR 4; WARFARIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ALCOHOLISM; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANGINA PECTORIS; ANTICOAGULATION; ARTERIAL THROMBOEMBOLISM; ARTICLE; ASTHENIA; BLEEDING; BLOATING; BODY MASS; BODY TEMPERATURE DISORDER; BRAIN HEMORRHAGE; BULLOUS DERMATITIS; CHILDBIRTH; CHILL; CHOLESTATIC HEPATITIS; COMA; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG CONTAMINATION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DYSPEPSIA; DYSPNEA; ECZEMA; EDEMA; ERYTHEMA; FATIGUE; FEVER; FLATULENCE; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HEPATITIS; HERB DRUG INTERACTION; HUMAN; HYPERCOAGULABILITY; HYPERTRANSAMINASEMIA; HYPOTENSION; IMMOBILIZATION; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LETHARGY; LIMB AMPUTATION; LUNG EMBOLISM; MALAISE; NAUSEA; OBESITY; OSTEOPOROSIS; PAIN; PALLOR; PARESTHESIA; PARTIAL THROMBOPLASTIN TIME; PRURITUS; RASH; SKIN NECROSIS; STROKE; SYNCOPE; THORAX PAIN; THROMBOCYTE ACTIVATION; THROMBOPHILIA; TREATMENT DURATION; UNCONSCIOUSNESS; URTICARIA; VASCULITIS; VENOUS THROMBOEMBOLISM; VOMITING;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; DRUG CONTAMINATION; DRUG MONITORING; FOOD-DRUG INTERACTIONS; HEMORRHAGE; HEPARIN; HUMANS; HYPERSENSITIVITY; INJECTIONS, SUBCUTANEOUS; NECROSIS; OSTEOPOROSIS; SKIN DISEASES; SUBCUTANEOUS TISSUE; THROMBOCYTOPENIA; WARFARIN;

EID: 84864096755     PISSN: 00115029     EISSN: 15578194     Source Type: Journal    
DOI: 10.1016/j.disamonth.2012.04.002     Document Type: Article

References (40)

1. Hull R.D., Raskob G.E., Rosenbloom D., et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990, 322:1260-1264.
2. Campbell N.R., Hull R.D., Brant R., et al. Aging and heparin-related bleeding. Arch Intern Med 1996, 156:857-860.
3. Walker A.M., Jick H. Predictors of bleeding during heparin therapy. JAMA 1980, 244:1209-1212.
4. Hyers T.M., Agnelli G., Hull R.D., et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998, 114:561S-578S.
5. Bernardi E., Piccioli A., Oliboni G., et al. Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism-an overview. Thromb Haemost 2000, 84:22-26.
6. Levine M.N., Raskob G., Landefeld S., et al. Hemorrhagic complications of anticoagulant treatment. Chest 1995, 108:276S-290S.
7. Graafsma Y.P., Prins M.H., Lensing A.W., et al. Bleeding classification in clinical trials: observer variability and clinical relevance. Thromb Haemost 1997, 78:1189-1192.
8. Levine M.N., Raskob G., Landefeld S., et al. Hemorrhagic complications of anticoagulant treatment. Chest 1998, 114:511S-523S.
9. Landefeld C.S., Beyth R.J. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993, 95:315-328.
10. Martel N., Lee J., Wells P.S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005, 106:2710-2715.
11. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-1335.
12. Girolami B., Prandoni P., Stefani P.M., et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003, 101:2955-2999.
13. Warkentin T.E., Sheppard J.A., Sigouin C.S., et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006, 108:2937-2941.
14. Visentin G.P., Ford S.E., Scott J.P., et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994, 93:81-88.
15. Greinacher A., Pötzsch B., Amiral J., et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994, 71:247-251.
16. Kelton J.G., Smith J.W., Warkentin T.E., et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994, 83:3232-3239.
17. Ziporen L., Li Z.Q., Park K.S., et al. Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 1998, 92:3250-3259.
18. Li Z.Q., Liu W., Park K.S., et al. Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine hit-like monoclonal antibody. Blood 2002, 99:1230-1236.
19. Visentin G.P., Moghaddam M., Beery S.E., et al. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med 2001, 138:22-31.
20. Newman P.M., Chong B.H. Further characterization of antibody and antigen in heparin-induced thrombocytopenia. Br J Haematol 1999, 107:303-309.
21. Rauova L., Poncz M., McKenzie S.E., et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005, 105:131-138.
22. Patel R., Lim Z., Dawe S., et al. Heparin-induced skin necrosis. Br J Haematol 2005, 129:712.
23. Hirsh J., Bauer K.A., Donati M.B., et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133:141S-159S.
24. Dahlman T.C. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993, 168:1265-1270.
25. Information on heparin sodium injection United States Food and Drug Administration, Accessed October 8, 2008. http://www.fda.gov/cder/drug/infopage/heparin/default.htm.
26. Medwatch United States Food and Drug Administration, Accessed October 8, 2008. http://www.fda.gov/medwatch/safety/2008/heparin_recall.htm.
27. Greinacher A., Warkentin T.E. Contaminated heparin. N Engl J Med 2008, 359:1291-1292.
28. Blossom D.B., Kallen A.J., Patel P.R., et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008, 359:2674-2684.
29. Kishimoto T.K., Viswanathan K., Ganguly T., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008, 358:2457-2467.
30. Massonnet-Castel S., Pelissier E., Bara L., et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis 1986, 16:139-146.
31. Schindewolf M., Schwaner S., Wolter M., et al. Incidence and causes of heparin-induced skin lesions. CMAJ 2009, 181:477-481.
32. Schindewolf M., Kroll H., Ackermann H., et al. Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia. J Thromb Haemost 2010, 8:1486-1491.
33. Bank I., Libourel E.J., Middeldorp S., et al. High rate of skin complications due to low-molecular-weight heparins in pregnant women. Thromb Haemost 2003, 1(4):859-861.
34. Wysowski D.K., Nourjah P., Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007, 167:1414-1419.
35. Nazarian R.M., Van Cott E.M., Zembowicz A., et al. Warfarin-induced skin necrosis. J Am Acad Dermatol 2009, 61(2):325-332.
36. Coumadin (warfarin) package insert 2010, Bristol-Myers Squibb, Princeton, NJ.
37. Ansell J., Hirsh J., Hylek E., et al. Pharmacology and management of the vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133:160S-198S.
38. Gardiner P., Phillips R., Shaughnessy A.F. Herbal and dietary supplement-drug interactions in patients with chronic illnesses. Am Fam Physician 2008, 77:73-78.
39. Pradaxa Package Insert 2010, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.
40. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.